

# PRACTICE

## HEALTH AND DRUG ALERTS

### Persistent pulmonary hypertension of the newborn and maternal use of SSRIs

**Reason for posting:** Major depressive disorders affect one in 10 women of reproductive age, and selective serotonin reuptake inhibitors (SSRIs), with their generally favourable efficacy and safety profiles, are the most common medications used to treat these conditions. However, the results of a recent case-control study suggest that women taking the drugs in the latter half of their pregnancy may have an increased risk of their offspring developing persistent pulmonary hypertension of the newborn (PPHN).<sup>1</sup>

**The drugs:** PPHN is a rare but serious and sometimes fatal (about 10%–20% of the time) respiratory condition (Box 1, Box 2). In the current study, 377 women who delivered children with PPHN were enrolled. They were matched to 836 control women and their infants who did not have PPHN. Six months after delivery the women were asked to identify medications used in pregnancy, health history and demographic variables including age, ethnicity, number of years of education, presence of diabetes, cigarette use, pre-

#### Box 1: Infants with persistent pulmonary hypertension of the newborn

- are born at or near term (> 34 weeks' gestation)
- are generally without other congenital anomalies
- have persistent elevation of pulmonary vascular resistance
- experience right-to-left shunting through a patent ductus arteriosus, foramen ovale or both
- have profound postnatal hypoxemia
- have severe respiratory failure requiring intubation and mechanical ventilation

pregnancy body mass index (BMI) and their infant's sex. The results showed use of the antidepressants in general (and SSRIs specifically) before 20 weeks' gestation was not associated with PPHN. However, after adjusting for maternal ethnicity, BMI and diabetes, women using SSRIs after 20 weeks' gestation were more likely to have a child with PPHN than matched controls (adjusted odds ratio [OR] 6.1, 95% confidence interval [CI] 2.2–16.8). Adjustment for factors such as smoking, alcohol intake and use of NSAIDs did not change the results. Of note, only about one in 20 children with PPHN had mothers who used antidepressants during their pregnancy (a proportion

#### Box 2: Possible associations with persistent pulmonary hypertension of the newborn

##### Fetal factors

- Male sex
- Meconium-stained amniotic fluid
- Neonatal sepsis
- Nonvertex presentation
- Pneumonia

##### Maternal factors

- Antenatal NSAID use
- Black or asian ethnicity
- Cesarean section
- Diabetes
- Fever
- Higher prepregnancy body mass index
- Lower educational level
- Maternal obesity
- Tobacco use
- Urinary tract infection

similar to the control group). SSRIs used included citalopram, fluoxetine, paroxetine and sertraline.

The potential mechanism of this adverse effect is not certain, but SSRIs, which pool in the fetal lungs, may inhibit nitric oxide synthesis.<sup>1</sup> Alternatively, increased serotonin levels may vasoconstrict pulmonary vessels, or cause pulmonary smooth muscle cell proliferation and increased pulmonary vascular resistance.<sup>1</sup>

### Canadian Adverse Reaction Newsletter Bulletin canadien des effets indésirables

To receive the Newsletter and health product Advisories free by email, join Health Canada's **MedEffect** mailing list.

Go to [www.hc-sc.gc.ca/dhbp-mps/medeff/subscribe-abonnement/index\\_e.html](http://www.hc-sc.gc.ca/dhbp-mps/medeff/subscribe-abonnement/index_e.html).

Inscrivez-vous à la liste **MedEffet** de Santé Canada pour recevoir gratuitement par courriel le Bulletin et les Avis au sujet des produits de santé. Rendez-vous à l'adresse [www.hc-sc.gc.ca/dhbp-mps/medeff/subscribe-abonnement/index\\_f.html](http://www.hc-sc.gc.ca/dhbp-mps/medeff/subscribe-abonnement/index_f.html).

**Report adverse reactions toll free to Health Canada  
Signaler sans frais des effets indésirables à Santé Canada**

Tel./Tél. : 866 234-2345 • Fax/Téléc. : 866 678-6789

Canada

**What to do:** These findings add to previously described problems of congenital malformations and neonatal adaptation syndrome seen in some pregnant women using SSRIs.<sup>2,3</sup> Although it is important to acknowledge the limitations of case-control studies (including their inability to establish causation and possible confounding by unmeasured variables) and a possible recall bias, the relative risk increase (6-fold) seen here is dramatic. Nevertheless, the absolute risks of having a child with PPHN still remain low. Women taking SSRIs in the second half of their pregnancy will see their baseline risk of having a child with PPHN increase from 0.1% to 0.6%, an absolute increase of

0.5%. Although there is a 99.5% chance that such a woman's child would be unaffected, the number needed to harm is only 200. Women should be made aware of this potential adverse effect and the benefits and risks of treatment considered on a patient-by-patient basis. Infants born to women using the drugs should be monitored closely postpartum. It's not clear whether lower SSRI doses were protective. Alternate antidepressants had a similar but slightly lower risk of PPHN relative to controls (adjusted OR 3.2, 95% CI 1.3–7.4).

**Eric Wooltorton**  
CMAJ

## REFERENCES

1. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354:579-87.
2. Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. *CMAJ* 2005;173:1320-1.
3. Koren G, Matsui D, Einarson A, et al. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *CMAJ* 2005;172:1457-9.

All Health and Drug Alerts are posted online ahead of print and are available at [www.cmaj.ca](http://www.cmaj.ca). This article was posted on May 2, 2006.

## CMA Physician Manager Institute



P

M

I

**A five-level credit program exclusively for physicians designed to develop superior leadership and management skills**

### In-house PMI

A practical, cost effective and focused training opportunity held on-site for medical leaders and managers

### For information:

tel 800 663-7336 or 613 731-8610 x2319 (PMI)  
or x2261 (In-house PMI) • [professional\\_development@cma.ca](mailto:professional_development@cma.ca)  
[cma.ca/leadership.htm](http://cma.ca/leadership.htm)

Approved for RCPSC, CFPC, CCHSE credits.

## PMI workshop 2006 schedule

### PMI I/II

11–13 June/14–16 June  
24–26 Sept./27–29 Sept.

Ottawa, ON  
Calgary, AB

### PMI III/IV

5–7 Nov./8–10 Nov.

Vancouver, BC

### PMI V

20–22 Oct.

Vancouver, BC

ASSOCIATION  
MÉDICALE  
CANADIENNE



CANADIAN  
MEDICAL  
ASSOCIATION